100, 100: Ending Diabetic Eye Disease, Forever
Breakthrough T1D has supported eye disease research since its beginning, and has driven discoveries that have reduced the risk of blindness by 95%.
Top Researchers Gather for the 15th ATTD Conference
Leading researchers gathered, in person, for the annual meeting of the ATTD Conference (April 27-30), featuring 30+ studies presented by Breakthrough T1D scientists.
ATTD Conference Brings Together Top Minds in Diabetes Research
Diabetes researchers from all over the world gather for the ATTD Conference, which will take place in-person and online from April 27-30 in Barcelona.
100, 100: Breakthrough T1D Research Leads to a New Class of Glucose-Lowering Agents
You’ve seen the ads: Victoza®. Ozempic®. Trulicity®. But did you know that these drugs came about, in part, because of type 1 diabetes research?
FDA Approval of Senseonics Eversense® CGM for Use for Up to 6 Months
FDA approves Senseonics Eversense® E3, the first long-term implantable CGM system, and the E3 includes technology that extends the use for up to 6 months.
100 Years, 100 Breakthrough T1D Scientists: The BB Rat—An Animal Model of Type 1 Diabetes
In 1974, a colony of non-diabetic BB rats develops diabetes. Examination of their pancreases revealed that they had no beta cells.
Interview with our New Community Screening and Clinical Trial Education Director
Breakthrough T1D has a new community screening and clinical trials education director. She's been a volunteer and now staff since her daughter was diagnosed in 2002.
Insulin: A Story of Innovation
On January 11, 1922—100 years ago—14-year-old Leonard Thompson, who was diagnosed with diabetes 3 years earlier, became the first person to receive insulin.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal consumption.
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now in human clinical trials.
